An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Expanded access
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 01 Nov 2020 Status changed from recruiting to completed.
- 20 Dec 2013 New source identified and integrated (Barbara Ann Karmanos Cancer Institute: 2013-137).
- 25 Sep 2013 New trial record